Mitochondria are vital for cellular bioenergetics and play a central role in determining the point-of-no-return of the apoptotic process. As a consequence, mitochondria exert a dual function in carcinogenesis. Cancer-associated changes in cellular metabolism (the Warburg effect) influence mitochondrial function, and the invalidation of apoptosis is linked to an inhibition of mitochondrial outer membrane permeabilization (MOMP). On theoretical grounds, it is tempting to develop specific therapeutic interventions that target the mitochondrial Achilles' heel, rendering cancer cells metabolically unviable or subverting endogenous MOMP inhibitors. A variety of experimental therapeutic agents can directly target mitochondria, causing apoptosis induction. This applies to a heterogeneous collection of chemically unrelated compounds including positively charged a-helical peptides, agents designed to mimic the Bcl-2 homology domain 3 of Bcl-2-like proteins, ampholytic cations, metals and steroid-like compounds. Such MOMP inducers or facilitators can induce apoptosis by themselves (monotherapy) or facilitate apoptosis induction in combination therapies, bypassing chemoresistance against DNA-damaging agents. In addition, it is possible to design molecules that neutralize inhibitor of apoptosis proteins (IAPs) or heat shock protein 70 (HSP70). Such IAP or HSP70 inhibitors can mimic the action of mitochondrion-derived mediators (Smac/DIABLO, that is, second mitochondria-derived activator of caspases/direct inhibitor of apoptosis-binding protein with a low isoelectric point, in the case of IAPs; AIF, that is apoptosis-inducing factor, in the case of HSP70) and exert potent chemosensitizing effects.
Introduction
In recent times, molecular genetic evidence in favor of a direct implication of mitochondria in oncogenesis has been accumulating. Some polymorphisms in mitochondrial DNA influence the susceptibility to breast (Canter et al., 2005) and prostate cancer (Petros et al., 2005) . Mitochondrial DNA transversion mutations are associated with familial medullary thyroid carcinoma (AbuAmero et al., 2005) . The nucleus-encoded fumarate and succinate dehydrogenases genes (which code for mitochondrial enzymes) have been identified as tumorsuppressor genes that inhibit the development of renal cancer and pheochromocytoma, respectively (Isaacs et al., 2005; Lenders et al., 2005) . The targeted disruption of frataxin in the liver has been shown to induce hepatocellular carcinoma in mice (Thierbach et al., 2005) . These examples illustrate how mitochondrial genes and proteins can impact on oncogenesis.
Cancer cells manifest a series of metabolic changes, one of which is the so-called Warburg effect. Accordingly, even in the presence of oxygen, cancer cells tend to synthesize ATP mainly through anaerobic glycolysis, a phenomenon that requires high glucose uptake and causes local acidification owing to lactate production (Warburg, 1930 (Warburg, , 1956 ). The Warburg effect may involve a series of metabolic defects including unregulated, supernormal glucose uptake with upregulation of the rate-limiting steps of glycolysis (for instance driven by constitutive activation of the Akt pathway) (Elstrom et al., 2004) , as well as defects in mitochondrial respiration, as they manifest in cancer cells.
Cancer cells also tend to disable the mitochondrial pathway of apoptosis by suppressing signals that can cause mitochondrial outer membrane permeabilization (MOMP), which constitutes (one of) the major event(s) sealing the cell's fate (Ferri and Kroemer, 2001a) . Multistep tumorigenesis, as recapitulated in vitro, is intrinsically linked to apoptosis resistance (Hahn et al., 1999) , progressive dependence on glycolytic energy production and independence from mitochondrial energy production (Ramanathan et al., 2005) . On theoretical grounds, there are two mechanisms that can link the Warburg phenomenon to MOMP inhibition. On the one hand, it is conceivable that the metabolic alterations and MOMP inhibition are acquired independently. In this scenario, mutations of mitochondrial DNA would increase the likelihood of cancer cells to undergo apoptosis (Kujoth et al., 2005) , and only cells in which the apoptotic pathways are suppressed might be fit enough to participate in oncogenesis. On the other hand, the Warburg phenomenon could be mechanistically linked to MOMP inhibition. One connection is provided by hexokinase II, a glycolytic enzyme that may participate in the Warburg phenomenon and that also can interact with mitochondrial membranes to inhibit MOMP (Robey and Hay, 2005) . Another link is given by pathogenic mutations in the mitochondrial genome that may reduce spontaneous apoptosis in cancer cell lines (Shidara et al., 2005) .
Here, we will consider the cancer-relevant regulation of MOMP and discuss the molecular mode of action of MOMP inducers and of agents that enhance the proapoptotic activity of mitochondrial death effectors.
Mitochondrial membrane permeabilization: the central event of apoptosis
The most commonly used cancer therapeutics eliminate tumors by inducing apoptosis Kroemer, 2004, 2005) . Chemotherapy and radiation therapy, for instance, cause DNA damage, leading to activation of the proapoptotic members of the B-cell lymphoma protein 2 (Bcl-2) superfamily -a process known as the cell-intrinsic pathway. Other cancer drugs are designed to engage cell surface death receptors and activate apoptosis through a p53-independent signaling mechanism known as the cell-extrinsic pathway. Most chemotherapy agents and irradiation trigger tumor cell apoptosis through the intrinsic pathway, as an indirect consequence of cellular damage. Both apoptotic signaling pathways involve mitochondrial membrane permeabilization, a process also referred to as the 'central executioner' of apoptosis (Green and Kroemer, 1998; Ferri and Kroemer, 2001b) (Figure 1 ). During this process, the mitochondrial outer membrane (OM) and inner membrane (IM) are both permeabilized, resulting in the release of soluble proteins from the intermembrane space. As a consequence, a number of proteases and nucleases are activated to begin the process of breaking down the cell (Patterson et al., 2000) . MOMP culminates in the complete loss of the barrier function of the OM and the consequent release of potentially toxic proteins, which normally are secured in the intermembrane space. Such cytotoxic proteins include caspaseindependent death effectors (nucleases and proteases) as Figure 1 Schematic overviews of the interactions involved in mitochondrial apoptosis converging on the PTPC (upper panel) and p53 (lower panel). Please refer to the text for additional details. Abbreviations: ANT, adenine nucleotide translocator; Bak, Bcl-2 antagonist/killer; Bax, Bcl-2-associated X protein; Bcl-2, B-cell lymphoma 2 protein; BH3, Bcl-2 homology domain 3; CK, creatine kinase; CypD, cyclophilin D; GSK3b, glycogen synthase kinase 3b; HK, hexokinase; Mn-SOD, manganese-dependent superoxide dismutase; mtCLIC/CLIC4, mitochondrial chloride intracellular channel/chloride intracellular channel 4; p53AIP1, p53-regulated apoptosis-inducing protein 1; PBR, peripheral-type benzodiazepine receptor; PTPC, permeability transition pore complex.
Chemotherapy and mitochondria L Galluzzi et al well as caspase activators, namely cytochrome c (cyt c, which activates the so-called apoptosome, a caspase activation complex including dATP, apoptosis-protease activating factor 1, that is Apaf-1, and procaspase-9), second mitochondria-derived activator of caspases/ direct inhibitor of apoptosis-binding protein with a low isoelectric point (Smac/DIABLO) and the high temperature requirement protein A2 (Omi/HtrA2) (which both function as inhibitors of caspase-inhibitory IAPs) (Danial and Korsmeyer, 2004) . The consequence of a partial IM permeabilization, which does not result in the release of matrix proteins but contribute to cell death, is that mitochondria lose their vital metabolic and redox functions (Zamzami et al., 1995; Metivier et al., 1998; Poncet et al., 2003) . Mitochondrial permeabilization is therefore recognized as a crucial checkpoint in programmed cell death of both normal and cancer cells.
Dozens or perhaps hundreds of signal transducing molecules act on mitochondria to induce or to inhibit MOMP (Tables 1 and 2 ). Although many of the factors that regulate mitochondrial permeabilization are known, the exact molecular mechanisms are controversial (Green and Kroemer, 2004; Perfettini et al., 2005; Zamzami et al., 2005) . During recent years, some insights into how MOMP is regulated have been gained.
Bax and Bak. Mouse embryonic fibroblasts (MEF) lacking both Bcl-2-associated X protein (Bax) and Bcl-2 antagonist/killer (Bak), two tumor-suppressor gene products from the proapoptotic arm of the Bcl-2 family, are resistant to different types of apoptotic stimuli Boya et al., 2005) and are more susceptible to rat sarcoma viral oncogene homolog (Ras)-mediated transformation than control cells . Bak is normally associated with OM, where it interacts with the voltage-dependent anion channel isoform 2 (VDAC2), which prevents its activation (Cheng et al., 2003) . Upon apoptosis induction Bak fully inserts into OM, as a result of a conformational change. Bax translocates from the cytosol to OM where it inserts and oligomerizes. Recombinant Bax can permeabilize liposomal membranes and form channels in planar lipid bilayers. Such studies suggested that Bax alone (Saito et al., 2000) (or associated with VDAC) (Shimizu et al., 1999) would form a conduit selective for small proteins such as cyt c (14.5 kDa). Bax combined with another proapoptotic protein of the Bcl-2 family, t-Bid, can permeabilize cardiolipin-containing liposomes in vitro to fluorescent dextran of size up to 2000 kDa (Kuwana et al., 2002) , correlating with the fact that apoptotic MOMP occurring in true cells is nonselective and affects all soluble intermembrane proteins, irrespective of their size (Patterson et al., 2000) . The mechanisms of membrane permeabilization induced in isolated mitochondria exposed to recombinant Bax depends on its oligomerization status, although oligomerization by itself may be insufficient for the induction of MOMP (Poncet et al., 2004) . Bax oligomers trigger cyclosporin A (CsA)-resistant cyt c release, while Bax monomers cause permeabilization through a pathway that can be inhibited by CsA (Gogvadze et al., 2001 ). This suggests a functional interaction between Bax and the CsAsensitive permeability transition pore complex (PTPC) (Marzo et al., 1998b; Belzacq et al., 2003) . Another protein outside of the PTPC that may be required for Bax-mediated MOMP is the so-called modulator of apoptosis 1 (MAP-1) (Baksh et al., 2005; Tan et al., 2005) .
Other proapoptotic Bcl-2 family members. Truncated Bid (t-Bid) is thought to induce apoptosis through the induction of a conformational change in Bax (or Bak), thereby triggering its full membrane insertion and oligomerization (Wei et al., 2000) . Accordingly, Bax À/ À Bak À/À MEF are relatively resistant to t-Bid-induced cyt c release . Nevertheless, it has also been suggested that t-Bid forms membrane-inserted homotrimers that do not interact with other mitochondrial proteins (Grinberg et al., 2002) . Moreover, t-Bid can form channels in planar lipid bilayers (Schendel et al., 1999) and destabilize them (Kudla et al., 2000) . The question of whether t-Bid's effects on mitochondria depend on interactions with sessile mitochondrial proteins, including a CsA target, has been controversial . One study indicates that t-Bidmediated permeabilization occurs in a two-step process, the first step (CsA-independent) leading to a partial (B15%) cyt c release, and the second step (CsAsensitive) causing the total cyt c release and remodeling of the mitochondrial ultrastructure . t-Bid-mediated MOMP has also been reported to involve obligatory interactions with carnitine palmitoyl transferase 1 (Giordano et al., 2005) or mitochondrial carrier homolog 2 (Grinberg et al., 2005) . Other proapoptotic proteins from the Bcl-2 family such as Bcl-2 antagonist of cell death (Bad), Bcl-2-interacting mediator of cell death (Bim), and Noxa are believed to induce apoptosis via an interaction with either Bax or Bak and/or by generating stable complexes with antiapoptotic Bcl-2/Bcl-X L (Adams, 2003) .
p53. This transcription factor can induce MOMP through two pathways (Perfettini et al., 2004b) . First, p53 can trans-activate a large panel of genes whose products locate to mitochondria. Such proteins include proapoptotic members of the Bcl-2 family (such as Bax, Noxa, p53-upregulated modulator of apoptosis/Bcl-2-binding component 3 (Puma/Bbc3)), the mitochondrial chloride intracellular channel/chloride intracellular channel 4 (mtCLIC/CLIC4), redox-active enzymes (such as proline oxidase and ferredoxin reductase) and proteins that operate through a yet unknown mode of action (such as maspin). Second, p53 can translocate to mitochondria, where it presumably interacts with members of the Bcl-2 family, namely Bcl-2, Bcl-X L (Mihara et al., 2003) , Bax (Chipuk et al., 2004) and Bak (Leu et al., 2004) as well as with other proteins, such as glycogen synthase kinase-3b (Watcharasit et al., 2003) or the manganese-dependent superoxide dismutase (Zhao et al., 2005) . Which among these interactions are relevant for MOMP induction by p53 is subject of an ongoing controversy. Irrespective of this, p53 can induce MOMP both in a transcription-dependent and in a transcription-independent fashion.
Voltage-dependent anion channel. VDAC the most abundant OM protein, has been reported to be required for apoptosis induction. VDAC is normally responsible for the exchange of metabolites between the cytosol and the mitochondrial intermembrane space. Microinjection of VDAC-specific antibodies or of a VDAC-specific inhibitor (Ko¨nig's polyanion) can reduce apoptosis induced by microinjected Bax (Ferri et al., 2000) , etoposide, paclitaxel, and staurosporine (Shimizu et al., 2001) . VDAC might by sufficient to permeabilize membranes, since VDAC proteoliposomes release cyt c in the presence of reactive oxygen species (ROS) (Madesh and Hajnoczky, 2001 ). BCL-2 and Bcl-X L have been reported to close VDAC, both in liposomes and in plain lipid bilayers. This effect can be mimicked by peptides corresponding to the BH4 domains, which are present in Bcl-2 and Bcl-X L yet absent from the proapoptotic proteins Bax, Bak, Bid, Bim and Noxa (Shimizu et al., 2000b) . In proteoliposomes, Bax or Bak (but not Bid) might interact with VDAC to create composite channels sufficiently large to release cyt c (Shimizu and Tsujimoto, 2000) . VDAC therefore appears to be the prime cyt c release channel in the OM, and its activity might be suppressed by Bcl-2 or Bcl-X L , or increased by Bax or Bak. However, there is perhaps another completely different mechanism through which VDAC might participate in apoptosis induction. Upon growth factor withdrawal, indeed, the exchange of metabolites (ATP, ADP, NADH, creatine and creatine phosphate) across OM might be reduced, due to the closure of VDAC (Vander Heiden et al., 2001) . Although the exact reasons for VDAC closure have not been elucidated, it has been suggested that an increased IM transmembrane potential (DC m ) would directly affect OM, creating a local voltage gradient and closure of VDAC. This OM DC m causing the closure of VDAC would be dissipated by Bcl-2 by virtue of its capacity to create ion-permeable channels (Vander Heiden et al., 2001) . Of note, there are several VDAC isoforms (VDAC1, VDAC2, VDAC3). Although there is no systematic study that has addressed the contribution of VDAC isoforms to apoptosis, it appears that VDAC1 is proapoptotic (Zaid et al., 2005) , while VDAC2 might be antiapoptotic, acting as an endogenous inhibitor of Bak (Cheng et al., 2003) .
Adenine nucleotide translocator. ANT is a protein that interacts with VDAC and other proteins, such as cyclophilin D (CypD), to form the PTPC at the contact sites between IM and OM (Beutner et al., 1998; Marzo et al., 1998b) . ANT, the most abundant IM protein, is an antiporter responsible for the exchange of ATP and ADP. ANT can form nonspecific pores that have been proposed to mediate IM permeabilization and osmotic matrix swelling, to which OM rupture follows when the surface area of the IM (with its folded cristae) exceeds that of the OM. Alternatively, the conformation of ANT, which is modulated by ANT ligands (Brustovetsky et al., 2002) and CsA-sensitive interactions with CypD, might indirectly impinge on VDAC activity . When reconstituted into liposomes or into planar lipid bilayers, ANT can form nonspecific channels in response to proapoptotic agents such as atractyloside, Ca 2 þ (Brustovetsky et al., 2002) , lonidamine and the HIV-1 viral protein R (Vpr) . Moreover, ANT channel formation is enhanced by Bax (Marzo et al., 1998a) , and inhibited by Bcl-2 . However, mouse knockout studies led to the conclusion that ANT would not (always) be required for apoptotic MOMP (Kokoszka et al., 2004) . Recent evidence suggests that some ANT isoforms (ANT1, ANT3) are apoptogenic while others are not (ANT2) (Schubert and Grimm, 2004; Zamora et al., 2004) . In 2005, a fourth ANT isoform (ANT4) has been identified in man (Dolce et al., 2005) and mouse (Rodic et al., 2005) by means of two independent experimental approaches. The role of this isoform in apoptosis has not been elucidated yet.
Cyclophilin D. CypD (gene name: Ppif, for peptidylprolyl cis-trans isomerase F) is the pharmacological target of CsA in mitochondria. Hepatocyte mitochondria from control and Ppif À/À mice exhibited identical cyt c release patterns when treated with recombinant Bax or t-Bid (truncated Bid) proteins, whereas Ppif À/À mitochondria were protected from Ca 2 þ -induced cyt c release (Baines et al., 2005; Nakagawa et al., 2005) . This indicates that the MOMP induced by proapoptotic Bcl-2 family members can occur independently from CypDregulated events. In contrast, cells from Ppif À/À mice were protected against cell death induced by H 2 O 2 , Ca 2 þ ionophores and ischemia/reperfusion (Baines et al., 2005; Nakagawa et al., 2005) , indicating the existence of CypD-dependent death modalities.
MOMP-inhibitory proteins in mitochondria.
It is well established that the antiapoptotic tumor-suppressors Bcl-2 and Bcl-X L are OM proteins that act as barriers against membrane permeabilization (Kroemer, 1997) . It is controversial, however, how they stabilize the membrane -it could be by neutralizing the function of proapoptotic Bcl-2 family members, by inhibiting VDAC, by neutralizing ANT channel activity, by physicochemical effects on the lipid bilayer or by a combination of all of these (Green and Kroemer, 2004) . Hexokinase II, a mitochondrial protein that catalyses the first step of glycolysis, has also been shown to inhibit apoptosis. Hexokinase II transcription and mitochondrial translocation are both induced by the Akt-mediated antiapoptotic signaling pathway (Gottlob et al., 2001) . As a possibility, hexokinase II might inhibit the VDAC-mediated membrane insertion of Bax (Pastorino et al., 2002).
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Mitochondrial lipids. The lipid composition of the IM is significantly different from that of other intracellular membranes. The IM is essentially cholesterol-free, and it is the only eukaryotic membrane containing the phosphoglyceride cardiolipin. The IM also contains a relatively high portion of negatively charged phospholipids such as phosphatidylserine. These specific features might determine the preferential insertion of certain proteins into mitochondrial membranes. For instance, t-Bid preferentially associates with cardiolipin-containing membranes (Lutter et al., 2000) , which might explain why t-Bid is enriched at the contact sites between IM and OM. Cationic ampholytes -molecules whose structure includes both a hydrophobic and a hydrophilic cationic moiety -might also be expected to preferentially redistribute to IM, not only driven by the DC m , but also because of the acidic phospholipids present in the membrane. It is important to note that the composition of mitochondrial lipids changes during apoptosis, with cardiolipin oxidation as a prominent feature (Sandra et al., 2005) . This might facilitate the desorption of cyt c from IM (Ott et al., 2002) . Of note, it appears that a growing number of MOMP-regulatory proteins are involved in lipid metabolism. This applies to phospholipid scramblase 3, carnitine palmitoyl transferase 1 (Table 1) , and perhaps also t-Bid, which has been suggested to have a lipid transferase activity (Sandra et al., 2005) . Mitochondria isolated from tumor cells are intrinsically resistant to the induction of MOMP, when compared to mitochondria from normal cells (Chandra et al., 2002) . This may be due to the upregulation of MOMP-inhibitory proteins or to the downregulation of MOMP promoters. Indeed, antiapoptotic proteins from the Bcl-2 family are widely overexpressed in cancer while proapoptotic Bcl-2 antagonists and p53 often undergo loss-of-function mutations (Green and Kroemer, 2004) . Outside of the Bcl-2 family, prominent examples of MOMP inhibitors that are overexpressed in cancer are hexokinase II (Mathupala et al., 1997) , as well as the peripheral-type benzodiazepine receptor (PBR) (Casellas et al., 2002) , a mitochondrial protein interacting with ANT and VDAC . Cancer cells also undergo a shift in the expression pattern of the ANT isoenzymes, reducing expression of the proapoptotic ANT1 isoform and increasing expression of the antiapoptotic protein ANT2 (Giraud et al., 1998) . Another example is given by the oncoprotein mucin 1 (DF3/MUC1), that translocates to mitochondria in response to heregulin (ligand for ErbB-2, a growth factor receptor) and inhibits MOMP in tumor cells (Ren et al., 2006) . From these observations, it appears why advances in the understanding of cancer-specific deregulation of MOMP are not only desirable, but crucial. Indeed, the identification of relevant MOMP regulators might yield novel therapeutic approaches for cancer therapy.
Direct inducers of mitochondrial membrane permeabilization
Reportedly, a number of conventional chemotherapeutics can induce cell death by permeabilizing mitochondrial membranes. These include 2-chloro-2 0 -deoxyadenosine (Genini et al., 2000) , etoposide (Robertson , 2000) , and paclitaxel (Kidd et al., 2002) . High doses of these drugs, however, are often required to obtain such effects, casting doubts on the possibility that they truly induce cell death via direct MOMP induction. A number of other mitochondrion-permeabilizing molecules exist and several drugs are being developed (Table 3) . The physicochemical and pharmacological profiles of such mitochondrion-targeted agents allows for their classification in several subgroups.
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Bcl-2 targeted drugs. Multiple approaches have been developed to target Bcl-2 family members in cancer cells. For example, a recombinant chimeric protein that contains interleukin-2 fused to Bax kills interleukin-2 receptor-bearing cells in vitro (Aqeilan et al., 1999) . Similarly, Bak can be targeted to the Fce receptor by fusing it to the constant region of the immunoglobulin E molecule. This fusion protein has been shown to selectively induce apoptosis in vitro in IgE producing cells, such as mast cells and basophils (Belostotsky and Lorberboum-Galski, 2001 ). An antisense oligonucleotide designed to downregulate the expression of Bcl-2 (Genasense, G3139, Oblimersen) is being evaluated in phase I/II trials against solid and hematopoietic neoplasia (Tolcher, 2005) . Such antisense oligonucleotides, which are relatively nontoxic to normal cells, might be particularly useful for treating tumors that express high levels of Bcl-2. However, it has not yet been formally proven that Bcl-2-targeted antisense oligonucleotides exert their antitumor effects solely by downregulating Bcl-2 and it remains possible that they provoke more unspecific effects, for instance by stimulating the innate immune response.
BH3 mimetics. Several small molecules that disrupt the interaction between Bcl-X L and Bak have been identified and shown to occupy the BH3-binding pocket of Bcl-X L . These molecules induce apoptosis by blocking the BH3-mediated heterodimerization between Bcl-2 family members, thus acting as BH3 mimetics (Degterev et al., (Gincel and Shoshan-Barmatz, 2004) Abbreviations: ANT, adenine nucleotide translocator; Bad, Bcl-2 antagonist of cell death; Bak, Bcl-2 antagonist/killer; Bax, Bcl-2-associated X protein; Bcl-2, B-cell lymphoma protein 2; Bcl-w, synonym of Bcl-2L2 (Bcl-2 like protein 2); Bcl-X L , B-cell lymphoma X protein, long splicing isoform; BH3, Bcl-2 homology domain 3; CK, creatine kinase; DF3/MUC1, mucin 1; ERK, extracellular signal-regulated kinase; HK, hexokinase; JNK, c-Jun N-terminal kinase; Mcl-1, myeloid cell leukemia sequence 1 (Bcl-2-related); Mn-SOD2, manganese-dependent superoxide dismutase 2; p38 MAPK, mitogen-activated protein kinase of 38 kDa; PBR, peripheral-type benzodiazepine receptor; PHGPx, phospholipid hydroperoxide glutathione peroxidase; PKA, protein kinase A; PKCe, protein kinase Ce; PKG, cGMP-dependent protein kinase; PTPC, permeability transition pore complex; VDAC, voltage-dependent anion channel.
Chemotherapy and mitochondria L Galluzzi et al 2001). The small molecule ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (HA14-1), which binds to the surface pocket of Bcl-2, may induce apoptosis in a similar manner . Antimycin A, a compound that inhibits complex III of the respiratory chain, and its methoxy derivative (which does not block complex III) also bind to the BH3-binding hydrophobic groove of Bcl-2 and Bcl-X L , thereby permeabilizing purified mitochondria expressing Bcl-X L (Tzung et al., 2001) . Peptides that correspond to the BH3 domains of Bax (BaxBH3) or Bcl-2 (Bcl2BH3) permeabilize mitochondria in a CsAsensitive fashion. When fused to the Antennapedia plasma membrane translocation domain (Ant), which facilitates cellular uptake, BaxBH3Ant and Bcl2BH3Ant induce mitochondrial permeabilization via a mechanism that is not inhibited by overexpression of Bcl-2 or Bcl-X L (Vieira et al., 2002) . Peptides with an improved stability that can induce apoptosis of Bcl-2 expressing cells in vitro and in vivo have been developed (Walensky et al., 2004 ) and a small inhibitory BH3 mimetic has yielded promising preclinical results (Oltersdorf et al., 2005) . Similar agents might be used alone or in combination with other molecules to overcome multidrug resistance in cancer cells that overexpress Bcl-2-like antiapoptotic proteins.
Peripheral-type benzodiazepine receptor ligands. Synthetic ligands of the PBR (such as 1-(2-chlorophenyl)-Nmethyl-N-(1-methylpropyl)-3-isoquinoline-carboxamide -known as PK11195 -or the benzodiazepine 4 0 -chlorodiazepam -Ro5-4864) can induce apoptosis or sensitize cells to apoptosis induction, thereby overcoming the cytoprotective effects of Bcl-2 or Bcl-X L . This chemosensitizing effect has been demonstrated in several tumor cell lines, in vitro, as well as in SCID mice transplanted with human cancer cells (Decaudin et al., 2002) . In these models, treatment with PBR ligands was not able to induce cell death on its own. However, when used in combination with etoposide, cisplatin, arsenite, lonidamine, anti-CD95 antibody, dexamethasone or ceramide, these agents were cytotoxic and neutralized the antiapoptotic potential of Bcl-2 . Nonetheless, there is strong evidence against the possibility that the apoptogenic or chemosensitizing effects of PBR ligands would be truly due to a direct interaction with the PBR. The doses of PBR ligands required to obtain such cytotoxic effects, indeed, are several orders of magnitude higher than the K d of the high affinity PBR-binding site. Moreover, the knockdown of PBR with specific small interfering RNAs does not reduce the chemosensitizing effects of PBR ligands in vitro . Hence, PBR ligands either act on a low affinity binding site present on mitochondria yet distinct from PBR, or via a completely different mechanism. In fact, the proapoptotic action of PK11195 might involve the induction of ROS generation (Walter et al., 2004) or the inhibition of the multidrug resistance pumps (Walter et al., 2005) .
Adenine nucleotide translocator ligands. A number of different agents are able to permeabilize ANT-containing proteoliposomes, but not plain liposomes, suggesting that they might be used to specifically permeabilize mitochondrial membranes. These include cytotoxic drugs such as lonidamine, arsenite and 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphtalene carboxylic acid (CD437) (Belzacq et al., 2001a) as well as the aforementioned BaxBH3 peptide. (Vieira et al., 2002) . All these compounds induce channel formation when ANT is reconstituted into lipid bilayers, but it is not known whether they act directly on ANT or at the ANT/lipid interface. They are likely, however, to promote a conformational change in ANT, since ANT-containing proteoliposomes permeabilization can be suppressed by the natural ANT ligands ATP and ADP (Belzacq et al., 2001a) . Lonidamine showed remarkable effects on benign prostate hypertrophy and is undergoing clinical trials for the treatment of malignant tumors. In addition to CD437, other retinoids were shown to induce apoptosis through mitochondrial pathways, independently from the binding to nuclear receptors. Among these, all-trans-retinoic acid (atRA) (Notario et al., 2003) , but not N-(4-hydroxyphenyl)retinamide (4-HPR) nor [(4-nitrophenyl)amino][2,2,4,4-tetramethyl thiochroman-6-yl)amino] methane-1-thione (SHetA2) (Chun et al., 2003) , induces CsA-sensitive mitochondrial permeability transition (MPT) in isolated organelles and selectively binds to ANT. On theoretical grounds it is possible that ANT inhibitors might exhibit a selective toxicity on particular cell populations, depending on the expression of the ANT isoforms (Giraud et al., 1998) . Thus, it might be conceivable to create ANT-specific agents that would selectively kill ANT2-overexpressing cancer cells or tumor cells having accumulated mutations in the mitochondrial genome.
Steroid analogs. A number of agents that act on mitochondria possess a steroid-like core structure. For instance, this applies to avicins, betulinic acid, CD437, resveratrol, and the bile acid glycochenodeoxycholic acid. These agents might perturb the lipid composition of mitochondrial membranes and induce lipid rafts, which in turn may favor MOMP (Garofalo et al., 2005) . Avicins can form channels in synthetic membranes (Li et al., 2005) . Betulinic acid has the interesting ability to selectively kill tumor cells, including neuroblastoma, medulloblastoma, glioblastoma and Ewing sarcoma cells, yet to spare many normal cell types (Fulda and Debatin, 2005) . Isolated mitochondria from different cell types, including normal murine hepatocytes, are permeabilized by betulinic acid, and this effect is prevented by CsA, the ANT ligand bongkrekate, as well as by Bcl-2 overexpression (Fulda et al., 1998a) . It is unclear, however, through which receptor (if any) betulinic acid acts on mitochondria.
Cationic ampholytes. Reportedly, an increased intrinsic DC m correlates with increased malignancy (apoptosis resistance and tumor progression) (Heerdt et al., 2003 (Heerdt et al., , 2005 , suggesting that cytotoxic agents whose accumulation into the cells is driven by a high DC m may have selective effects on cancer cells. The specific physicochemical properties of the IM and the net deficit of positive charges on the inner side of the IM results in the DC m -driven accumulation of cationic lipophils in the mitochondrial matrix. Recently, cationic ceramide derivatives, but not their neutral counterparts, have been reported to buildup in isolated and in situ mitochondria in an energy-dependent manner (Novgorodov et al., 2005) . Following the Nernst equation, positively charged agents sufficiently lipophilic to insert in or to cross cellular membranes enrich in IM and/or in the mitochondrial matrix. Any compound with mild detergent-like properties could permeabilize mitochondria if it reached high enough concentrations in and around the IM. Representatives of such compounds are F16 and FTY720. The peptide D KLAKLAKK LAKLAK or (KLAKLAK) 2 (K ¼ lysine, L ¼ leucine, A ¼ alanine) is a cationic ampholyte, being an a-helical peptide that possess positive charges clustered on one side of the helix. (KLAKLAK) 2 directly permeabilizes mitochondria when added to isolated organelles. Moreover, it can be fused to targeting peptides that interact with surface receptors expressed on angiogenic endothelial cells in tumors (Ellerby et al., 1999) or on prostate vasculature (Arap et al., 2002) . These fusion peptides are translocated into the cytoplasm, and induce apoptosis via MOMP (Ellerby et al., 1999) specifically in the targeted cell population. Thus, a prostate-targeted (KLAKLAK) 2 peptide has been used to target prostate tumors in mice (Arap et al., 2002) . Treatment of mice with this peptide postponed the development of cancer in model of spontaneously developing prostate adenocarcinoma (Arap et al., 2002) . Similarly, (KLAK-LAK) 2 has been fused to a peptide that inhibits the ErbB-2 receptor kinase (Fantin et al., 2005) . The resulting fusion protein specifically affects mitochondria of cells that express ErbB-2, but not those of cells lacking ErbB-2 expression, causing MOMP and DC m dissipation. In addition, this peptide has been used to induce massive apoptosis in vivo, in mice carrying established human breast cancer xenografts (Fantin et al., 2005) . These experiments provide a proof-ofconcept for the strategy of targeting toxic hybrid molecules to cancer cells, first to surface receptors and then to mitochondria.
Redox-active compounds. Agents that promote oxidative reactions can also be used to permeabilize the mitochondrial membrane. These compounds include arsenite (which depletes glutathione), 2-methyl-1,4-naphthoquinone (menadione, which undergoes futile redox cycles on the respiratory chain), and thiol-crosslinking agents such as diazenedicarboxylic acid bis5N,N-dimethylamide (diamide), bismaleimidohexane (BMH) and dithiodipyridine (DTDP), which are able to overcome cytoprotection by Bcl-2 and to cause ANT thiols oxidation (Costantini et al., 2000) . Arsenite, which permeabilizes purified mitochondria in vitro (Belzacq et al., 2001a; Larochette et al., 1999) has also pro-oxidant effects and is used nowadays for the routine treatment of acute promyelomonocytic leukemia (Kroemer and de The´, 1999) . The organic arsenic chemical 4-(N-(S-glutathionylacetyl)amino)phenylarsenoxide (GSAO) directly affects mitochondria, where it crosslinks the matrix-facing thiols of Cys-160 and Cys-257 of ANT, thus causing MOMP (Don et al., 2003) . Surprisingly, this agent is particularly toxic for proliferating endothelial cells of tumors yet it spares the other cell types. This may be linked to the particular characteristics of endothelial cells which lack the multidrug resistance-associated proteins capable of extruding GSAO from the cytoplasm (Dilda et al., 2005) .
Photosensitizing agents. Photosensitizing agents that act on mitochondria -some of which by interacting with PBR -generate ROS when exposed to light. Locally generated ROS might then act on mitochondrial PTPC components, including VDAC and ANT, and cause the formation of protein-permeable conduits or nonspecific ion channels (Belzacq et al., 2001b) . The photosensitizer hypericin reportedly detaches hexokinase from mitochondria (Miccoli et al., 1998) , whereas the phthalocyanine photosensitizer Pc 4 causes the photochemical destruction of Bcl-2 (Xue et al., 2001) . Altogether, available data suggest that photosensitizing agents can target mitochondria, where they induce apoptosis independently from the p53 status, even in Bax-negative cells (Chiu et al., 2005) .
Mitochondrial proapoptotic factors as chemotherapeutic agents As outlined above, apoptotic MOMP results in the release of a plethora of proapoptotic factors from the intermembrane space. Such factors include Smac/ DIABLO, a protein that exerts much of its proapoptotic function by neutralizing IAPs, which function as caspase inhibitors. The binding of Smac/DIABLO to IAPs is mediated by a relatively short stretch of aminoacids located in the N-terminus of the protein . Several investigators have developed peptidomimetics in which the N-terminus of Smac/DIABLO is fused to plasma membrane translocation domains, thus allowing for its intracellular delivery. Such Smac/ DIABLO peptidomimetics have been successfully used to induce apoptosis in vivo, in orthotopically implanted glioblastoma xenografts (Fulda et al., 2002) . Moreover, small molecule Smac/DIABLO analogs have been developed and have been shown to sensitize to apoptosis induction several tumor cell lines (Li et al., 2004; Bockbrader et al., 2005) , including MDA-MB-231 breast cancer cells characterized by high levels of IAPs (Bockbrader et al., 2005 ).
An alternative strategy can exploit the properties of apoptosis-inducing factor (AIF), a mitochondrial flavoprotein that normally resides in the intermembrane space where it participates in redox reactions (Miramar et -, RR-, ADP-and SODsensitive, o-phenanthroline-prevented MPT in isolated mitochondria.
(Hermes-Lima, 1995)
ABT-737
In vitro and in vivo, in mouse models
Small molecule inhibitor of Bcl-2, Bcl-X L and Bcl-w. (Oltersdorf et al., 2005) all-trans-retinoic acid In vitro Induces CsA-sensitive, Ca 2+ -dependent MPT in isolated mitochondria, by binding to ANT. Activity independent from the binding to nuclear receptors. 
Betulinic acid Kills neuroectodermal tumors in vitro and in mice
Induces PT in isolated mitochondria. (Fulda et al., 1998a; Fulda et al., 1998b) Steroid-related structure (triterpenoid).
Benzyl isothiocyanate Chemoprevention Induces MOMP in isolated mitochondria. Bismaleimido-hexane In vitro Induces ADP-and ATP-sensitive PT in ANT proteoliposomes and CsA-sensitive PT in isolated mitochondria. Oxidize ANT on Cys 56, irrespective of Bcl-2 levels.
BMAP-28
In vitro Induces CsA-sensitive, Ca 2+ -potentiated (Risso et al., 2002 ) MOMP in isolated mitochondria. -and Pi-potentiated, potentialdependent swelling in isolated mitochondria. (Lemeshko et al., 2005) Butylated hydroxylanisole Chemoprevention Induces PT in isolated mitochondria. (Yu et al., 2000) Butyrate Chemoprevention Induces PT in isolated mitochondria and ANT proteoliposomes. (Jan et al., 2002; Heerdt et al., 2003) Carbenoxolone
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In vitro
Induces CsA-and BA-sensitive MOMP in isolated Ca 2+ -loaded mitochondria. (Salvi et al., 2005) 
CD437
In vitro Induces PT in isolated mitochondria and ANT proteoliposomes. Steroid-related structure. (Marchetti et al., 1999; Belzacq et al., 2001a) CDDO
In vitro
Induced cyt c release in isolated mitochondria. Steroid-related structure (triterpenoid).
( Konopleva et al., 2004) Citrinin
Induces dose-and Ca 2+ -dependent, (Da Lozzo et al., 1998) CsA-, RR-and ATP-Mg 2+ -sensitive, DTT-potentiated, BHT-and catalase-insensitive MPT in isolated mitochondria.
Clodronate
Osteoclasts (bone metastases) Adenosine metabolite. Inhibits ANT. (Lehenkari et al., 2002) Daphnetoxin
In vitro
Induces CsA-, catalase-and DTT-sensitive MPT in isolated mitochondria. (Peixoto et al., 2004) Steroid-related structure (diterpenoid).
Diamide
In vitro
Induces ADP-and ATP-sensitive PT in (Petronilli et al., 1994; Costantini et al., 2000) ANT proteoliposomes and CsA-, DTT-and NEM-sensitive PT in isolated mitochondria. Oxidize ANT on Cys 56, irrespective of Bcl-2 levels.
Dithiodipyridine
In vitro Induces ADP-and ATP-sensitive PT in ANT proteoliposomes and CsA-sensitive PT in isolated mitochondria. Oxidize ANT on Cys 56, irrespective of Bcl-2 levels.
DNOC and DNP
In vitro Induce Ca 2+ -dependent, CsA-catalase-sensitive MTP in isolated mitochondria. Uncouplers. (Castilho et al., 1997) 
DTNB
In vitro Induces CsA-, Mg 2+ -and PPi-sensitive, (Wudarczyk et al., 1996 ) Ca 2+ -and CATR-potentiated MPT in energized isolated mitochondria. Redox-cycling agent.
Etoposide
Multiple neoplasias Can induce CsA-and Bcl-2-sensitive MOMP in isolated mitochondria, at high concentration. (Robertson et al., 2000) F16
In vitro
Cationic lipophilic agent that induces MOMP in isolated mitochondria. (Fantin et al., 2002) Chemotherapy and mitochondria (Bernardi, 1992; Kowaltowski et al., 1996) Uncoupler, classical MPT inducer.
FTY720
Immunosuppressive Cationic lipophilic agent that induces PT in isolated mitochondria. (Nagahara et al., 2000) Glycyrrhetinic acid
In vitro Induces CsA-and BA-sensitive, Ca 2+ -dependent MOMP in isolated mitochondria. (Salvi et al., 2003) GSAO Angiogenesis inhibitor in vitro and in vivo
Induces PT in isolated mitochondria and oxidizes thiols of ANT.
( Don et al., 2003) HA14-1 In vitro Bcl-2 ligand that induces MOMP via an oxidative mechanism. An et al., 2004) Hyperforin
In vitro
Induces MOMP in isolated mitochondria. (Schempp et al., 2002) HOFQ
Its oxidation products induce PT in isolated mitochondria. Photosensitizer compound toxic also in the dark. In vivo (mice) Cationic lipophilic peptide with a helices acting on inner membranelipids. (Ellerby et al., 1999) Lonidamine Glioblastoma (phase II) Induces PT in isolated mitochondria and ANT proteoliposomes. Oudard et al., 2003) Mastoparan
At low doses, it induces oligomycin À and (Pfeiffer et al., 1995) CsA-sensitive, Ca 2+ -and Pi-facilitated MPT in isolated mitochondria. The MPT at higher concentrations is Ca 2+ -independent and CsA-insensitive.
Menadione
In vitro Induces CsA-, NEM-, and BQ-sensitive, Ca
2+
-dependent MPT in isolated mitochondria. Redox-cycling agent. (Petronilli et al., 1994; Palmeira and Wallace, 1997) 
MT21
In vitro ANT ligand that induces MOMP in isolated mitochondria. (Watabe et al., 2000; Machida et al., 2002) Paclitaxel Multiple neoplasias Can induce CsA-and Bcl-2-sensitive MOMP in isolated mitochondria, at high concentration.
( Kidd et al., 2002) Phenylarsine oxide In vitro Induces CsA-and BHT-sensitive, (Lenartowicz et al., 1991 ) Ca 2+ -potentiated MPT in isolated mitochondria. Thiol-crosslinking agent, classical MPT inducer.
Photoactivated merocyanine 540 CL
In vitro
Induces PT in isolated mitochondria. (Pervaiz et al., 1999) Chemotherapy and mitochondria L Galluzzi et al 
PK11195
In vitro and in animals Induces PT in isolated mitochondria. (Hirsch et al., 1998; Banker et al., 2002; Decaudin et al., 2002; Muscarella et al., 2003; Gonzalez-Polo et al., 2005 ) PBR ligand but may act on different locations.
Pristimerin
In vitro Induces CsA-insensitive cyt c release from isolated mitochondria, not associated with MPT. Resveratrol Chemoprevention Induces PT in isolated mitochondria. (Hirsch et al., 1998; Banker et al., 2002; Decaudin et al., 2002; Muscarella et al., 2003) Steroid-related structure.
SAHB peptide
In vitro and in animals Mimics the BH3 domain of Bid and binds to Bcl-X L in mitochondria. (Walensky et al., 2004) Taurine chloramine In vitro Induces PT in isolated mitochondria, in a CsA-and Bcl-2-sensitive fashion.
( Klamt and Shacter, 2005) tert-butylhydroperoxide In vitro Induces CsA-, NEM-and DTT-sensitive, (Petronilli et al., 1994 ) Ca 2+ -dependent MPT in isolated mitochondria. Induces oxidative stress, followed by thiol crosslinking. Classical MPT inducer.
Thyroid hormones (T 3 , T 4 and to a less extent T 2 and reverse T 3)
In vitro
Induce dose-and Ca 2+ -dependent, CsA-, RR-, DTT-and catalase-sensitive MPT in isolated mitochondria. (Castilho et al., 1998) 
TT2 and TT13
In vitro Induce Ca
2+
-dependent, RR-, CsA-, BA-and decylubiquinonesensitive (Wang et al., 2006) MPT in isolated mitochondria.
Unconjugated bilirubin
In vitro Induces CsA-, UCD-and TUDC-sensitive MPT and cyt c release in isolated mitochondria. (Rodrigues et al., 2000) Verteporfin plus light Photodynamic therapy Induces PT in isolated mitochondria, and ANT proteoliposomes. Can bind to PBR. (Belzacq et al., 2001b) Note that only drugs that have been shown to have direct membrane-permeabilizing effects on mitochondria are listed in this table. Abbreviations: ANT, adenine nucleotide translocator; AQ, 1,4-anthraquinone analog; BA, bongkrekic acid; Bax, Bcl-2-associated X protein; BaxBH3, peptide corresponding to the BH3 domain of Bax; Bcl-2, B-cell lymphoma protein 2; Bcl-w, synonym of Bcl-2L2 (Bcl-2 like protein 2); Bcl-X L , B-cell lymphoma X protein, long splicing isoform; BH3, Bcl-2 homology domain 3; BHT, butylhydroxytoluene; Bid, BH3 interacting domain death agonist; BMAP-28, bovine myeloid antimicrobial peptide of 28 residues; BQ, 1,4-benzoquinone; BTM-P1, Bacillus thuringiensis subsp. medellin peptide 1 (sequence VAPIAKYLATALAKWALKQG-FAKLKS); CATR, carboxyatractyloside; CD437, 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphtalene carboxylic acid; CDDO, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid; citrinin, (3R,4S)-4,6-dihydro-8-hydroxy-3,4,5-trimethyl-6-oxo-3H-2-benzopyran-7-carboxylic acid; CsA, cyclosporin A; cyt c, cytochrome c; diamide, diazenedicarboxylic acid bis 5N,N-dimethylamide; DNOC, 4,6-dinitro-o-cresol; DNP, 2,4-dinitrophenol; DTNB, 5,5 0 -dithiobis(2-nitrobenzoic acid); DTT, dithiothreitol; FCCP, carbonyl cyanide p-(trifluoromethoxy)phenylhydrazone; FTY720, 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol; GSAO, 4-(N-(S-glutathionylacetyl)amino)phenylarsenoxide; HA14-1, ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate; HOFQ, 4-hydroxymethyl-1,6,8-trimethylfuro[2,3-h]quinolin-2(1 H)-one; menadione, 2-methyl-1,4-naphthoquinone; mastoparan, the peptide INLKALAALAKKIL-NH 2 ; MOMP, mitochondrial outer membrane permeabilization; MPT, mitochondrial permeability transition; NEM, N-ethylmaleimide; PBR, peripheral-type benzodiazepine receptor; PK11195, 1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinoline-carboxamide; Pi, inorganic phosphate; PPi, inorganic pyrophosphate; PT permeability transition; reverse T 3 , 3,5 0 ,3 0 -triiodo-L-thyronine; RR, ruthenium red; SAHB, stabilized alpha-helix of Bcl-2 domains; SOD, superoxide dismutase; T 2 , 3 0 ,5 0 -diiodo-L-thyronine; T 3 , 3,5,3 0 -triiodo-L-thyronine; T 4 , L-thyroxine; TT, triptycene synthetic analog; TUDC, tauroursodeoxycholate; UCD, ursodeoxycholate.
Chemotherapy and mitochondria
L Galluzzi et al glutathione levels (Cande et al., 2004b) and allows for optimal assembly or maintenance of respiratory chain complexes I and III (Vahsen et al., 2004) . Upon apoptosis induction, AIF translocates to the nucleus where it contributes to chromatin condensation via a direct interaction with DNA (Ye et al., 2002; Vahsen et al., 2006) and recruits other proteins into the 'degradosome', which mediates chromatinolysis Cande et al., 2004a) . Microinjection of recombinant AIF is sufficient to induce hallmarks of apoptosis (chromatin condensation, rounding up of cells, phosphatidyl serine exposure) . Similarly, transfection of cells with an AIF mutant lacking the mitochondrial localization sequence in the N-terminus, misdirects AIF to the cytosol and to the nucleus, and results in cell killing (Loeffler et al., 2001) .
Recently, a chimeric protein containing an ErbB-2-specific antibody in the C-terminus and the cytotoxic moiety of AIF in the N-terminus has been shown to direct AIF to ErbB-2-expressing cancer cells, causing their demise (Yu et al., 2006) . This strategy of tumor killing could be used for anticancer therapy in vivo, as demonstrated in mice xenotransplanted with human ErbB-2-overexpressing cancer cells when the chimeric protein was produced by Jurkat T-lymphoma cells that were coinoculated (Yu et al., 2006) .
Another AIF derivative is ADD70 (for AIF-derived decoy of heat shock 70 kDa protein (HSP70)). As a matter of fact, the peptide-binding domain of HSP70 can interact with AIF and HSP70 can inhibit the translocation of AIF to the nucleus, retaining it within the cytosol . The HSP70-binding domain within AIF has been determined , and this domain has been transfected into a variety of cell types, conferring a marked chemosensitizing effect in response to DNA damaging agents and tyrosine kinase inhibitors . The same effect was not found in cells that lack HSP70 expression, suggesting that it is truly due to the neutralization of the antiapoptotic effects of HSP70. ADD70 mediated chemosensitization relied upon both an enhanced translocation of AIF to the nucleus and an increased activation of caspases . These results illustrate the possibility of designing a new class of HSP70 inhibitors that may facilitate the induction of cell death (Figure 2 ).
Concluding remarks
Most of the currently used cytotoxic anticancer therapeutics have no clear-cut cell specificity, yet tend to kill tumor cells more efficiently than normal cells. Based on this empiric observation, it may be hoped that a novel class of mitochondrion-targeted agents could also kill tumor cells with an acceptable therapeutic index. Future will tell which, if any, among the compounds capable of inducing MOMP (or their look-alikes) will withstand clinical evaluation and for which precise tumors they will be useful, alone or in combination with other drugs. Nonetheless, it appears tempting to generate very specific drugs (for instance agents that selectively act on only one of the Bcl-2 family members), to target cytotoxic agents (first) to a tumor-specific surface receptor (and then to mitochondria) or to imagine protocols that will cause tumor cells to undergo immunogenic cell death . In the latter scenario, a 'bystander effect' would be elicited, in which the immune system would contribute to the eradication of residual tumor cells, allowing for a complete and permanent therapy response. As it stands, these are theoretical considerations that await urgent experimental and clinical verification, for the sake of medical progress.
Abbreviations ADD70, AIF-derived decoy of heat shock protein 70; AIF, apoptosis-inducing factor; Akt, v-akt murine thymoma viral oncogene homolog; ANT, adenine nucleotide translocator; Bad, Bcl-2 antagonist of cell death; Bak, Bcl-2 antagonist/ killer; Bax, Bcl-2-associated X protein; Bcl-2, B-cell lymphoma protein 2; Bcl-X L , B-cell lymphoma X protein, long splicing isoform; BH, Bcl-2 homology domain; Bid, BH3 interacting domain death agonist; Bim, Bcl-2-interacting mediator of cell death; CD437, 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphtalene carboxylic acid; CsA, cyclosporin A; CypD, cyclophilin D; cyt c, cytochrome c; DC m , mitochondrial transmembrane potential; ErbB-2, v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2; GSAO, 4-(N-(S-lutathionylacetyl)amino)phenylarsenoxide; HSP70, heat shock 70 kDa protein; IAP, inhibitor of apoptosis protein; IM, mitochondrial inner membrane; MEF, mouse embryonic fibroblasts; MOMP, mitochondrial outer membrane permeabilization; Noxa, synonym of PMAIP1 (phorbol-12-myristate-13-acetateinduced protein 1); OM, mitochondrial outer membrane; PBR, peripheral-type benzodiazepine receptor; PK11195, 1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxamide; Ppif, peptidyl-prolyl cis-trans isomerase F; PTPC, permeability transition pore complex; Puma/Bbc3, p53-upregulated modulator of apoptosis/Bcl-2-binding component 3; Ras, rat sarcoma viral oncogene homolog; ROS, reactive oxygen species; Smac/DIABLO, second mitochondria-derived activator of caspases/direct inhibitor of apoptosisbinding protein with a low isoelectric point; VDAC, voltage-dependent anion channel. Figure 2 IAPs and HSP70 exert their antiapoptotic activity by binding to and inactivating apoptosis executioners such as caspases and AIF, respectively. Chemosensitization of cancer cells may be achieved via a treatment with MPT inducers, promoting the mitochondrial release of apoptogenic factors (i.e. Smac/DIABLO), in association with peptidomimetics (for instance, ADD70), able to inhibit specific protein-to-protein interactions. Published crystallographic data allowed the use of the following structures for the construction of this figure: AIF, residues 128-608D540-559 ; Rattus norvegicus HSC70 substratebinding domain, residues 383-540 (Morshauser et al., 1999) ; caspase-3 heterodimeric catalytic domain with a nicotinic acid aldehyde inhibitor, residues 150-295/320-401 (Becker et al., 2004) ; two caspase-3 heterodimeric catalytic domains, residues 148-296D (157-160,223,248-253)/310-401 and 148-297D(157-160,223,248-253 )/310-401, complexed with XIAP Bir2 domains, residues 127-237 and 135-236D(170-178) (Riedl et al., 2001) ; Smac/DIABLO monomer, residues from 12 to 184 ; Smac/DIABLO homodimer, residues 1-157, complexed with two XIAP Bir3 domains, residues 256-344 and 256-357 . Owing to the lack of available crystallographic data, ADD70 is represented with the same structure of AIF, but only residues highlighted in orange are actually part of the peptide . Abbreviations: ADD70, AIF-derived decoy of heat shock protein 70; AIF, apoptosis-inducing factor; Bir, baculovirus inhibitor of apoptosis repeat; HSC70, heat shock cognate 70 kDa protein; HSP70, heat shock 70 kDa protein; IAP, inhibitor of apoptosis protein; Smac/DIABLO, second mitochondria-derived activator of caspases/direct inhibitor of apoptosis-binding protein with a low isoelectric point; XIAP, X-linked inhibitor of apoptosis protein.
